Amplifica Holdings назначила нового главного директора по разработке и члена совета директоров для ускорения создания терапии от облысения

Newswise — SAN DIEGO, Aug. 24, 2026 -- Amplifica Holdings Group, Inc. ("Amplifica"), a privately held, clinical-stage biopharmaceutical company developing novel therapies for hair growth, today announced the appointment of Hans Hofland, Ph.D., as Chief Development Officer and William Humphries to its board of directors. The appointments strengthen Amplifica's leadership with extensive experience spanning dermatology research and development, clinical translation, commercialization and corporate strategy as the Company advances its pipeline of product candidates designed to reactivate dormant hair follicles and promote new hair growth. "Hans and Bill bring distinct yet mutually reinforcing expertise at a pivotal stage for Amplifica," said Frank Fazio, President and Chief Executive Officer of Amplifica. "Hans has a strong record of advancing dermatology research programs into the clinic across multiple therapeutic modalities, while Bill has led and advised companies across the dermatology and broader healthcare sectors. Their perspectives will be invaluable as we execute our development strategy and build a leading company in hair-growth innovation." Dr. Hofland is a biopharmaceutical executive with more than 30 years of experience in drug discovery and development, translational research and clinical development. He has advanced dermatology therapeutics from early discovery through first-in-human studies across small molecules, nucleic acid-based therapies and biologics. His leadership experience includes roles at Connetics, Stiefel Laboratories, GlaxoSmithKline and Dermira, as well as co-founding Evommune and leading discovery and preclinical development at Turn Biotechnologies and Soleno Therapeutics. Dr. Hofland has contributed to 13 investigational new drug applications and helped advance 10 product candidates into clinical development and commercialization. He earned a Ph.D. in Pharmaceutical Sciences from Leiden University and completed postdoctoral training at the University of Pittsburgh. Mr. Humphries is an experienced healthcare executive and board director with deep expertise in dermatology, pharmaceuticals and contract development and manufacturing. He currently serves as Chief Executive Officer and a director of MedPharm and has served on the board of Aclaris Therapeutics since 2016. Previously, he led Alcami, Isosceles Pharmaceuticals, Ortho Dermatologics and Merz's North American business, and held senior leadership roles at Stiefel Laboratories and Allergan. Mr. Humphries also serves as a director of Cutera and has held board positions at several public and private healthcare companies. He earned a B.A. from Bucknell University and an M.B.A. from Pepperdine University. About Amplifica Holdings Group, Inc. Amplifica is a clinical-stage biopharmaceutical company focused on developing novel treatments for androgenetic alopecia (hair loss), a condition estimated to affect more than 50 million men and more than 30 million women in the United States alone. The Company is taking a nature-inspired scientific approach using molecular mechanisms designed to regrow natural hair. Amplifica has identified and isolated unique signaling molecules that stimulate hair follicles to regrow hair and is advancing product development programs and clinical trials to evaluate the safety and efficacy of its core technology, subject to applicable regulatory approvals. For more information, please visit amplificabio.com. Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will," "would," or the negative of these words or other similar expressions. These forward-looking statements are based on the Company's current beliefs and expectations. Forward-looking statements include, but are not limited to, statements regarding the potential efficacy of the Company's product candidates, the Company's expectations with respect to the development and commercialization of its product candidates and the initiation or completion of future clinical trials. Actual results may differ from the forward-looking statements expressed in this press release, and consequently you should not rely on these forward-looking statements as predictions of future events. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law. Contact(s) Company [email protected] Media EvolveMKD – [email protected]